Plaque Psoriasis

Arcutis has submitted a supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, according to a company press release.

Patients with psoriasis treated with higher doses of oral zasocitinib experienced greater improvement than those treated with placebo, according to a phase 2b study.

Ilumetri effectively restored the level of well-being of patients with moderate to severe plaque psoriasis to those of the general population, according to interim results released by Almirall.

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

A new antibody injection for the treatment of moderate to severe plaque psoriasis met all primary and key secondary endpoints in a phase 3 Chinese study, Innovent Biologics announced in a release.

Topical tapinarof cream showed significant improvement of moderate to severe atopic dermatitis while being well tolerated by adults and children down to age 2 years, according to two phase 3 clinical trials.

Simlandi injection, an interchangeable biosimilar to Humira, is now available in the U.S. for the treatment of psoriatic arthritis, plaque psoriasis and other conditions, Teva Pharmaceuticals and Alvotech announced in a press release.

Bristol Myers Squibb announced results from its long-term extension trial of Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the phase 2 STRIDE study.